Can Preemptive Cytomegalovirus Monitoring Be As Effective As Universal Prophylaxis When Implemented As the Standard of Care in Patients at Moderate Risk?
McGillicuddy JW, Weimert NA, Taber DJ, Turner A, Mitchell LA, Wray DW, Egidi MF, Kuppachi S, Hughes MG, Baliga PK, Chavin KD. Transplantation. 2010 May 27;89(10):1218-23
This retrospective study compares the strategy of universal prophylaxis to monitoring with serial PCR testing in patients at moderate risk for CMV disease post-transplant. All patients were CMV-positive pre-transplant and did not receive induction with a lymphocyte-depleting antibody. The incidence of CMV syndrome or infection was low in both groups, and costs were similar.
Related Articles:
- The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients
- The Pattern of Excess Cancer in Dialysis and Transplantation
- Desensitization in HLA-Incompatible Kidney Recipients and Survival
Recent Comments